Figure 1B shows that patients with low MZF1 expression had better overall survival than those with high expression. MZF1 expression in glioma cells (PT#3 and A172) was significantly higher than that in primary astrocytes (Figure 1C,D). This evidence concerns the gene MZF1 and central nervous system cancer.